Mutations of the β- and γ-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas by Ueda, M et al.
b-catenin, the vertebrate homologue of Drosophila Armadillo, is 
a multifunctional protein involved in 2 apparently independent
processes, acting as a cell–cell adhesion regulator when coupled
with cadherins (Barth et al, 1997) and as a transcriptional regulator
in the wingless/Wnt signal transduction pathway (Behrens et al,
1996). b-catenin forms complexes with Tcf and Lef-1 and func-
tions to transactivate downstream target genes of the Wnt pathway
(Behrens et al, 1996). Activation of the pathway by stabilization 
of b-catenin has been shown to be important in the development of
colorectal carcinoma, which is mainly caused by inactivat
ing mutations of the adenomatous polyposis coli (APC) tumour
suppressor gene or by activating mutations in exon 3 of the 
b-catenin gene that includes the glycogen synthase kinase-3b
(GSK-3b) phosphorylation site (Morin et al, 1997; Sparks et al,
1998). Mutations of the b-catenin gene have recently been impli-
cated in the initiation of melanomas and some colorectal carci-
nomas (Morin et al, 1997; Rubinfeld et al, 1997; Sparks et al,
1998). Although recent investigation have been focused on the role
of the APC/b-catenin/Tcf pathway in human tumorigenesis, there
have been very few reports on mutations of the b-catenin gene in a
variety of tumour types except for melanomas (Rubinfeld et al,
1997), colorectal (Kitaeva et al, 1997; Morin et al, 1997; Sparks
et al, 1998) and endometrioid carcinomas (Fukuchi et al, 1998;
Palacios and Gamallo, 1998). g-catenin has also been linked to the
APC/b-catenin/Tcf pathway by biochemical and genetic studies in
diverse organisms (Peifer, 1996). g-catenin shares strong amino
acid similarity with b-catenin and the NH2-terminal regulatory
motif is conserved between the 2 proteins. In addition, both
proteins bind APC, a-catenin, E-cadherin and Tcf (Rubinfeld et al,
1995; Sacco et al, 1995). Moreover, g-catenin exhibits signaling
activity similar to that of b-catenin in Xenopus (Karnovsky and
Klymkowsky, 1995), and functions as an oncogene (Kolligs et al,
2000). Therefore, activating mutations in the Wnt signalling
pathway could reasonably be expected to occur in the g-catenin
gene. In this report, we analysed the b- and g-catenin genes for
mutations in a large series of human lung, breast, kidney, cervical
and ovarian carcinoma cell lines. Our findings suggest mutations
in these genes are quite rare among the tumour types examined. 
MATERIALS AND METHODS 
DNA preparation 
Analyses were conducted on 93 lung, 9 breast, 6 kidney, 19
cervical and 7 ovarian carcinoma cell lines (Table 1). All lung,
breast, kidney and 7 (ME180, SiHa, CC19, Caski, C-33A, C-4i,
HeLa) cervical carcinoma cell lines were obtained from the
American Type Culture Collection. The other 12 cervical and all
ovarian carcinoma cell lines were kindly provided from the
Japanese institutes where each cell line was established. Detailed
information for cell lines examined is available from the authors
upon request. These cell lines were grown either in RPMI 1640 or
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McCoy’s medium (Sigma) supplemented with 10% or 15% fetal
calf serum at 37˚C in 5% CO2 atmosphere and were actively
growing prior to harvesting. The cells were disrupted with lysis
buffer (20 mM NaCl, 10 mM Tris-HCl (pH 8.0), 10 mM EDTA
(pH 8.0), 0.5% SDS, 50 mg ml–1 proteinase K), and then genomic
DNA was extracted with phenol-chloroform and precipitated with
ethanol using standard techniques. 
RNA isolation and cDNA preparation 
RNA was extracted from 20 lung, 9 breast, 5 kidney and 6 cervical
carcinoma cell lines (Table 1) by a combination of initial
phenol/chloroform extraction according to the RNA STAT-60
protocol (Tel-Test, Inc) and then SV-total RNA isolation kit
extraction (Promega, Inc) according to the supplier’s protocol.
Contaminating residual genomic DNA was removed by digestion
with RNase free DNase. cDNAs were prepared using at least 2 mg
of total RNA and SUPERSCRIPT II reverse transcriptase (Life
Technologies, Inc) with random hexamers as primers. 
PCR for b b- and g g-catenins 
For b-catenin, a genomic PCR fragment including codons 6–80 
in exon 3 encompassing the GSK-3 b phosphorylation site
was amplified (primers: forward, 5¢-attgatggagttggacatggc-3¢;
reverse, 5¢-ccagctacttgttcttgagtgaagg-3¢; Kitaeva et al, 1997). For
g-catenin, a genomic fragment encoding amino acids 1–57 of 
g-catenin and encompassing the NH2-terminal regulatory region 
was amplified (primers: forward, 5¢-ctcagtagccacgatggaggtg-3¢;
reverse, 5¢-ttcttgagcgtgtactggcg-3¢; Sparks et al, 1998). One ml of
the DNA template was amplified by PCR in a 50 ml reaction
containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2,
0.01% (w/v) gelatin, 200 mM dNTP, 0.5 mM each primer and 1.25
units Taq polymerase (Perkin Elmer Cetus). PCR was carried out
on a Perkin-Elmer GeneAmp PCR System 9600 with an initial
denaturation step at 96˚C for 3 min then 35 cycles at 94˚C for 1
min, 55˚C for 1 min, 72˚C for 2 min, and a final extention cycle at
72˚C for 10 min. Reaction products were visualized on a 1.5%
agarose gel with ethidium bromide. 
Reverse transcription (RT)-PCR for b b-catenin 
After RT of mRNA, 1 ml of the cDNA template was amplified by
PCR as described above using 6 primer pairs which cover the
entire coding region of the b-catenin cDNA. Detailed PCR condi-
tions and primer sequences used for amplification are available
from the authors upon request. Reaction products were visualized
as described above. 
Table 1 Human lung, breast, kidney, cervical and ovarian carcinoma cell lines examined
Lung carcinoma Breast carcinoma Cervical carcinoma
Small cell H2018 H1155 CRL1504a Squamous cell carcinoma
H2107 H1264 HTB121a
H69 H2141 H1155 HTB122a SKG-I
H82a H2171 H1299 HTB124a SKG-II
H187a H2195 H1334a HTB132a SKG-IIIa
H312 H2196 H1385 MCF-7a QG-H
H345 H2227 H1395 MDA231a QG-U
H378 SHP77 H1404 T470a YUMOTO
H446 COLO668 H1437 ZR75.1a HOKUG
H524 COLO699 H1438 ME180a
H526 NA17 H1573 Kidney carcinoma SiHa
H660 NE18 H1581a CC19a
H711 NU6-1 H1623 A498 Caskia
H719 umc19 H1648a PV10a C-33Aa
H735 UCLC11 H1650 KV6a C-4ia
H748 6LC20a H1693 ACHNa
H792 H1726 KRC-Ya Adenocarcinoma
H865 Non small cell H1781 Caki2a
H889 H1792 NUZ
H1045 H28a H1819 CAC-1
H1048a H125 H1869 OMC-4
H1062 H226a H2009 TCO-1
H1092 H290a H2052 TCO-2
H1105 H292a H2058 HeLaa
H1238 H320 H2077
H1284 H324 H2087 Ovarian carcinoma
H1304 H460a H2122a
H1339 H513a H2258 HOC-1
H1341a H522 NCIA549a HOC-21
H1417 H661a HAC-2
H1450 H720a SHIN-3
H1514 H727a HVOCA-II
H1522 H810 HMOA
H1607a H838 HUOA
H1618
H1876
aTotal RNAs were extracted and cDNAs were prepared for RT-PCR-SSCP analysis.66 M Ueda et al
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Single-strand conformational polymorphism (SSCP)
analysis 
The amplified fragments of the b- and g-catenin genes were
analysed for mutations by SSCP according to the method
described by Ilyas et al (1997) with some modifications. 5 ml of
PCR or RT-PCR products were mixed with 5 ml of loading buf
fer (95% formamide, 10 mM NaOH, 20 mM EDTA, 0.02%
bromophenol blue, 0.02% xylene cyanol), heat denatured at 95˚C
for 5 min, and immediately placed on ice. 8 ml of the mixture 
was run overnight at constant 8 W power on a 0.5 ´ Mutation
Detection Enhancement (MDE) vertical gel (FMC BioProducts)
containing 10% glycerol. The gel was stained by soaking for
15 min in a 0.1% solution of silver nitrate. After two quick washes
in distilled water, the gel was incubated in a solution of 0.15%
NaOH, 0.01% NaBH4 and 0.15% formaldehyde to visualize the
bands. 
Sequence analysis 
Polymorphisms in the b- and g-catenin genes, detected as aberrant
SSCP patterns, were sequenced. PCR or RT-PCR amplified DNA
fragments were purified using the QIAquick gel extraction kit
(QIAGEN) and directly sequenced using an Applied Biosystem
model 373 DNA sequencer (Perkin Elmer Cetus) with the primer
used for PCR or RT-PCR and a Dye Terminator Cycle Sequencing
FS Ready Reaction Kit (Applied Biosystems). Each mutation was
verified in both the sense and antisense directions. 
RESULTS 
Exon 3 was selected first for mutational analysis because it
encodes the NH2-terminal regulatory domain of b-catenin previ-
ously found to contain activating mutations (Morin et al, 1997;
Rubinfeld et al, 1997; Fukuchi et al, 1998; Palacios and Gamallo,
1998; Sparks et al, 1998). PCR and SSCP analysis of this region in
93 lung, 9 breast, 6 kidney, 19 cervical and 7 ovarian carcinoma
cell lines identified no point mutations but confirmed the existence
of a homozygous deletion in NCI-H28 (lung mesothelioma) as
shown in Figure 1A (Calvo et al, 2000). Neither deletions nor
mutations of exon 3 of the b-catenin gene were detected in the
other cell lines examined. To further investigate whether or not
genetic alterations of b-catenin exist in the complete coding
sequence, RT-PCR-SSCP analysis was conducted on 20 lung, 9
breast, 5 kidney and 6 cervical carcinoma cell lines using 6 primer
pairs which cover the entire coding region of the b-catenin cDNA.
As can be seen in Figure 1B, none of these primers amplified b-
catenin sequences from NCI-H28 cDNA, indicating that message
is either not made or is rapidly degraded. RT-PCR-SSCP analysis
on exons 4–6 also detected a variant band in HeLa (cervical adeno-
carcinoma) cells (Figure 2A). However, sequencing of the gel
purified RT-PCR product revealed a silent mutation (ACC to ACT,
Thr to Thr) at codon 214 in exon 5 (Figure 2C). These analyses of
over 100 tumours indicate that b-catenin mutations occur only
rarely in human lung, breast, kidney, cervical and ovarian carci-
nomas. 
If activation of the APC/b-catenin/Tcf signalling pathway is
critical for initiation of these tumour types, mutations in other
components of the pathway might be involved in the genesis of the
tumours. One candidate for such a component is g-catenin, which
shares strong amino acid similarity with b-catenin and the NH2-
terminal regulatory motif is conserved between the 2 proteins. To
address this possibility, we performed PCR-SSCP analysis on the
NH2-terminal regulatory region (codons 1–57) of g-catenin.
Among 134 cell lines examined, we found only two g-catenin
mutations (Figure 2B); a missense mutation at codon 19 (ACA to
ATA, Thr to Ile) in NCI-H1726 (squamous cell lung carcinoma)
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Figure 1 Mutational analysis of the b-catenin gene in lung carcinoma cells.
A, SSCP analysis of the PCR amplification of b-catenin exon 3 in 10 lung
carcinoma cell lines. Deletion of exon 3 of the b-catenin gene was found in
NCI-H28 (lung mesothelioma). B, SSCP analysis of the RT-PCR
amplification products from b-catenin exons 2–16 in 3 lung mesothelioma cell
lines and normal bronchial epithelial cells. Lanes 1–4 correspond to samples
from NCI-H513, NCI-H28, NCI-H290 (lung mesothelioma) and PDL6 (normal
bronchial epithelial cells), respectively. RT-PCR amplification was conducted
using 6 primer pairs which cover the entire coding region of the b-catenin
cDNA (a, exons 2–4; b, exons 4–6; c, exons 6–9; d, exons 8–10; e, exons
10–13; f, exons 13–16, respectively). All products are missing from NCI-H28,
indicating absence of b-catenin message 
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Figure 2 Mutational analysis of the b-catenin gene in cervical carcinoma
cells and the g-catenin gene in lung carcinoma cells. A, SSCP analysis of the
RT-PCR amplification products from b-catenin exons 4–6 in 6 cervical
carcinoma cell lines. An aberrant band is seen in HeLa (cervical
adenocarcinoma) which was excised, reamplified and sequenced. B, SSCP
analysis of the PCR amplification of g-catenin NH2-terminal regulatory region
in 9 lung carcinoma cell lines. Aberrant bands are seen in NCI-H1726
(squamous cell lung carcinoma) and NCI-H1048 (small cell lung carcinoma).
C, Electropherogram of b-catenin forward sequence in HeLa, indicating the
silent mutation at codon 214 in exon 5 (ACC to ACT, both coding for Thr).
D, Electropherogram of g-catenin reverse sequence in NCI-H1726, indicating
the missense mutation at codon 19 (ACA to ATA, Thr to Ile) b- and g-catenin mutations in human carcinomas 67
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(Figure 2D) and a silent mutation at codon 28 (TCG to TCA, Ser
to Ser) in NCI-H1048 (small cell lung carcinoma). Neither dele-
tions nor mutations of this region were detected in the other cell
lines examined. 
DISCUSSION 
A current hypothesis suggests that inactivation of APC or 
activating mutations of b-catenin may have similar functional 
and tumorigenic consequences in the human colon (Morin et al,
1997; Sparks et al, 1998). Consequently, b-catenin can behave 
as an oncogene, providing a potential alternative mechanism of
initiation in the pathway of colorectal carcinogenesis (Peifer,
1997). While mutations of the APC gene initiate approximately
85% of human colorectal carcinomas, the initiating event remains
unknown in the balance of cases (Kinzler and Vogelstein, 1996).
Recently, mutations in exon 3 of the b-catenin gene were found 
in 13 of 27 (48%) colorectal tumours lacking APC mutations,
suggesting that b-catenin might be mutated in a significant
minority of colorectal tumours (Sparks et al, 1998). Activating
mutations in b-catenin were also found in melanoma cell lines,
implying that b-catenin may act as an oncogene in a variety of
other carcinomas, including those without a clear association with
APC mutations (Rubinfeld et al, 1997). However, Kitaeva et al
(1997) demonstrated that no mutations were detected in the 8
melanoma cell lines. Moreover, Kitaeva et al (1997) and Candidus
et al (1996) reported that b-catenin mutations are uncommon in
human colorectal, gastric and breast carcinomas. 
In the present study, deletion of exon 3 of the b-catenin gene
was confirmed in NCI-H28 lung mesothelioma cells. However,
our results also indicate that the b-catenin deletion is sufficiently
large to eliminate detectable message. Deletion of the NH2-
terminal part of b-catenin was described for 2 cell lines originating
from signet ring cell carcinomas of the stomach (Oyama et al,
1994; Kawanishi et al, 1995), however, neither deletions nor muta-
tions of exon 3 of the b-catenin gene were detected in the other
133 cell lines examined. b-catenin mutations within armadillo
repeats 2 and 3 and outside the NH2-terminal regulatory domain
were also described in two colorectal carcinoma cell lines with
mutant APC (Ilyas et al, 1997). Here, we observed loss of expres-
sion for b-catenin in NCI-H28 lung mesothelioma cells and a
silent mutation at codon 214 in exon 5 in HeLa cervical adenocar-
cinoma cells. However, no genetic alteration outside exon 3 was
found in the other 38 cell lines examined. While the effects of
deletion for b-catenin are unknown, but its loss likely precludes
activation of the canonical Wnt signalling pathway. Further studies
are needed to clarify the molecular and biological consequences of
this deletion for NCI-H28 cells. 
The above analyses and previous reports indicate that b-catenin
mutations are uncommon in human lung, breast, kidney, cervical
and ovarian carcinomas. To further explore other potential mecha-
nisms of activating b-catenin signalling, we performed a muta-
tional analysis in the NH2-terminal regulatory region of the
g-catenin gene in these tumour cells. Only one potentially acti-
vating mutation was found in NCI-H1726 squamous cell lung
carcinoma cells among 134 cell lines examined. This mutation
resulted in Thr to Ile substitution at codon 19. Interestingly, the
same amino acid substitution has been demonstrated at codon 41
in exon 3 of the b-catenin gene in 2 endometrial carcinoma tissues
(Fukuchi et al, 1998). g-catenin shares strong amino acid simi-
larity with b-catenin, binds APC and Tcf, and exhibits signalling
activity similar to that of b-catenin (Karnovsky and
Klymkowsky, 1995; Rubinfeld et al, 1995; Sacco et al, 1995).
g-catenin mutation in H1726 cells might be involved in activation
of the APC/b-catenin/Tcf signalling pathway. Three APC-associ-
ated proteins, b-catenin, g-catenin and GSK-3b, have been linked
to the APC/b-catenin/Tcf pathway by biochemical and genetic
studies (Peifer, 1996; Kolligs et al, 2000). Sparks et al (1998)
reported that no mutations of the g-catenin and GSK-3b genes
were detected in colorectal tumours lacking APC mutations.
However, there have been very few reports on genetic alteration
of these genes in a variety of human tumour cells. Our present
results suggest that b-and g-catenins may not be a frequent target
of mutations involved in the pathogenesis of human lung, breast,
kidney, cervical and ovarian carcinomas. If the role of the
APC/b-catenin/Tcf-regulated transcription pathway is crucial for
oncogenesis of these tumours, alterations in other genes that
function in the Wnt signalling pathway must be elucidated. 
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